Clinical Trial

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Name: A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors — clinical trial record (NCT06859762)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Protocol Amendment History 4 amendments

This ClinicalTrials.gov record has been amended 4 times since 2025-03-04; most recent amendment 2026-01-12.

Status change: Not Yet Recruiting → Recruiting 2025-07-08

Trial Details

NCT Number	NCT06859762
Lead Sponsor	MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions	Advanced Solid Tumor
Enrollment	220 participants
Start Date	2025-07-02
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-01-14